Back to Media & Press

Zira Medical to Offer Licensed Clinical Consults for the Six Peptides Covered by New HHS Compounding Policy

Telehealth medical group will give digital health platforms licensed clinicians to evaluate patients and, when appropriate, prescribe BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon under HHS's interim policy

SHERIDAN, Wyo. – November 5, 2026 – Zira Medical, the licensed medical team behind digital health platforms and healthcare companies, today announced that it will offer clinical consults for the six peptides covered by a new interim policy from the U.S. Department of Health and Human Services. Under the policy, HHS will use enforcement discretion for 503A compounding of these peptides.

On October 30, HHS published an interim policy in the Federal Register covering six peptides, each in a specified form: BPC-157 acetate, Epitalon acetate, KPV acetate, MOTS-c acetate, Semax (free base) and TB-500 acetate. Under the policy, HHS does not intend to take enforcement action against state-licensed pharmacies, federal facilities and licensed physicians that compound these peptides under Section 503A, as long as they meet a defined set of conditions. Those conditions include:

  • A patient-specific prescription
  • Ingredients sourced from FDA-registered manufacturers, with a certificate of analysis
  • Use of only the forms and routes of administration the policy specifies
  • Reporting of serious adverse events to FDA's MedWatch program

In the notice, which HHS Secretary Robert F. Kennedy Jr. signed, HHS said it "believes that there is significant interest in the use of these peptides in compounding given the lack of availability of approved products," and that it is adopting the policy "to expand and improve patient access." The notice also states: "Compounded drugs are not FDA approved, which means FDA does not review their safety, effectiveness, or quality before they are marketed."

The policy is interim and non-binding, and HHS may revise or withdraw it. It does not make these peptides FDA-approved drugs, and it does not add them to FDA's 503A bulks list. Compounded products made under it remain unapproved drugs. The policy follows a July vote by FDA's Pharmacy Compounding Advisory Committee recommending the six peptides. FDA staff had recommended against adding them, citing safety concerns and limited evidence. HHS is accepting public comments through November 13, 2026.

"Patients have been buying these peptides online with no clinician involved and no way to know what's in the vial," said a Zira Medical spokesperson. "This policy creates a path that runs through a licensed clinician and a state-licensed pharmacy, and that's the path we want our partners on. Our clinicians will evaluate each patient individually and be upfront that these are unapproved, compounded products with limited evidence behind them. They'll prescribe only when it's appropriate and only within the policy's conditions. Telehealth companies will get a responsible way to offer peptide care, with the clinical oversight it needs."

Zira's peptide consults will be delivered by its licensed clinicians working inside each client's existing platform or EHR. Prescriptions will be filled at the client's choice of a state-licensed 503A pharmacy that meets the policy's conditions. Zira provides national coverage and is LegitScript certified. It offers per-consult pricing with no monthly platform fees, and its providers can start as soon as the next day once setup is complete.

Telehealth companies and healthcare organizations interested in adding peptide consults can contact info@ziramedical.com.

About Zira Medical

Zira Medical provides the licensed medical team for digital health platforms and healthcare companies, working inside their existing platforms and EHRs. With national coverage and LegitScript certification, Zira supports telehealth companies, DTC health brands, wellness providers and healthcare organizations. Learn more at ziramedical.com.

Media Contact

Source: HHS Federal Register notice

Schedule a Call